DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Novo Nordisk (NYSE: NVO)

56.48 -0.64 (-1.12%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVO $56.48 -1.12%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $56.32
Previous Close $57.12
Daily Range $55.77 - $56.71
52-Week Range $41.72 - $57.70
Market Cap $149.7B
P/E Ratio 0.00
Dividend (Yield) $0.73 (0.9%)
Ex-Dividend Date
Dividend Pay Date
03/19/15
03/31/15
Volume 2,328,616
Average Daily Volume 1,152,032
Current FY EPS $1.85

Sector

Healthcare

Industry

Drug Makers

Novo Nordisk (NVO) Description

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals. Website: http://www.novonordisk.com/

News & Commentary Rss Feed

How Will Big Pharma Fight Back Against MannKind?

Afrezza, an inhaled insulin, is officially on the market, and threatens many big industry leaders. How will big pharma fight back against the inhaled insulin threat?

Novo Nordisk And Its Promising Diabetes Drugs

Novo Nordisk's Saxenda Delays Onset of Type II Diabetes - Analyst Blog

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Heavy Early Morning Activity On Novo Nordisk A/S (NVO)

4 Reasons Why MannKind Could Succeed Where Pfizer Failed

9 years ago Pfizer tried to launch an inhaled insulin called Exubera to the market and it failed. Here are 4 reasons why Afrezza could succeed where Pfizer came up short.

The Weekender

Trophy Growth Stocks

The Best Company for Investing in the Diabetes Market

Diabetes spending is growing rapidly, and this company is the best way for investors to capitalize on the trend.

Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q1 2015 Results - Earnings Call Transcript

See More NVO News...

NVO's Top Competitors

NVO $56.48 (-1.12%)
Current stock: NVO
JNJ $100.14 (-1.00%)
Current stock: JNJ
NVS $102.73 (-1.46%)
Current stock: NVS
RHHBY $38.46 (2.83%)
Current stock: RHHBY